Rodrigo Donalisio da Silva, MD urges urologists to manage blunt and penetrating renal trauma conservatively. He uses the 2017 American Urological Association (AUA) Urotrauma guidelines to outline this conservative approach, specifically when to perform diagnostic imaging with intravenous (IV) contrast enhanced computed tomography (CT), non-invasive management strategies, proper injury classification, and when it is necessary to intervene.
Read More
Brain J. Flynn, MD, identifies the frequency of bladder neck contracture (BNC) following benign prostatic hyperplasia (BPH) surgery, prevention strategies, and endoscopic and surgical management. Furthermore, he explains his BNC management algorithm and the currently available lower urinary tract reconstructive procedure options.
Read More
Ronald F. Tutrone, Jr., MD, FACS, summarizes two Phase III clinical trials testing the safety and efficacy of fexapotide, a novel treatment for benign prostatic hyperplasia (BPH).
Read More
Lawrence I. Karsh, MD, FACS, discusses the use of SpaceOAR Hydrogel to reduce risk of rectal complications and improve quality of life (QOL) outcomes when treating prostate cancer with radiation therapy. He summarizes supporting clinical evidence, describes the physical application of the gel, and lists players currently offering coverage for the procedure.
Read More
Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapy (ADT) options, and the belief that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.
Read More